150 related articles for article (PubMed ID: 11589534)
1. Open trial of risperidone in 24 young children with pervasive developmental disorders.
Masi G; Cosenza A; Mucci M; Brovedani P
J Am Acad Child Adolesc Psychiatry; 2001 Oct; 40(10):1206-14. PubMed ID: 11589534
[TBL] [Abstract][Full Text] [Related]
2. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Shea S; Turgay A; Carroll A; Schulz M; Orlik H; Smith I; Dunbar F
Pediatrics; 2004 Nov; 114(5):e634-41. PubMed ID: 15492353
[TBL] [Abstract][Full Text] [Related]
3. An open trial of risperidone in young autistic children.
Nicolson R; Awad G; Sloman L
J Am Acad Child Adolesc Psychiatry; 1998 Apr; 37(4):372-6. PubMed ID: 9549957
[TBL] [Abstract][Full Text] [Related]
4. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study.
McDougle CJ; Holmes JP; Bronson MR; Anderson GM; Volkmar FR; Price LH; Cohen DJ
J Am Acad Child Adolesc Psychiatry; 1997 May; 36(5):685-93. PubMed ID: 9136504
[TBL] [Abstract][Full Text] [Related]
5. An open clinical trial of risperidone monotherapy in young children with autistic disorder.
Findling RL; Maxwell K; Wiznitzer M
Psychopharmacol Bull; 1997; 33(1):155-9. PubMed ID: 9133768
[TBL] [Abstract][Full Text] [Related]
6. A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone.
Masi G; Cosenza A; Mucci M; Brovedani P
J Clin Psychiatry; 2003 Sep; 64(9):1039-47. PubMed ID: 14628979
[TBL] [Abstract][Full Text] [Related]
7. Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness.
Malone RP; Maislin G; Choudhury MS; Gifford C; Delaney MA
J Am Acad Child Adolesc Psychiatry; 2002 Feb; 41(2):140-7. PubMed ID: 11837403
[TBL] [Abstract][Full Text] [Related]
8. Risperidone monotherapy in preschool children with pervasive developmental disorders.
Masi G; Cosenza A; Mucci M; De Vito G
J Child Neurol; 2001 Jun; 16(6):395-400. PubMed ID: 11417603
[TBL] [Abstract][Full Text] [Related]
9. Role of risperidone in children with autism spectrum disorder.
Chavez B; Chavez-Brown M; Rey JA
Ann Pharmacother; 2006 May; 40(5):909-16. PubMed ID: 16684811
[TBL] [Abstract][Full Text] [Related]
10. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
Research Units on Pediatric Psychopharmacology Autism Network
Arch Gen Psychiatry; 2005 Nov; 62(11):1266-74. PubMed ID: 16275814
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study.
Troost PW; Lahuis BE; Steenhuis MP; Ketelaars CE; Buitelaar JK; van Engeland H; Scahill L; Minderaa RB; Hoekstra PJ
J Am Acad Child Adolesc Psychiatry; 2005 Nov; 44(11):1137-44. PubMed ID: 16239862
[TBL] [Abstract][Full Text] [Related]
12. Risperidone treatment for juvenile bipolar disorder: a retrospective chart review.
Frazier JA; Meyer MC; Biederman J; Wozniak J; Wilens TE; Spencer TJ; Kim GS; Shapiro S
J Am Acad Child Adolesc Psychiatry; 1999 Aug; 38(8):960-5. PubMed ID: 10434487
[TBL] [Abstract][Full Text] [Related]
13. Open-label prospective trial of risperidone in combination with lithium or divalproex sodium in pediatric mania.
Pavuluri MN; Henry DB; Carbray JA; Sampson G; Naylor MW; Janicak PG
J Affect Disord; 2004 Oct; 82 Suppl 1():S103-11. PubMed ID: 15571784
[TBL] [Abstract][Full Text] [Related]
14. Risperidone use in children with Down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: a naturalistic study.
Capone GT; Goyal P; Grados M; Smith B; Kammann H
J Dev Behav Pediatr; 2008 Apr; 29(2):106-16. PubMed ID: 18349709
[TBL] [Abstract][Full Text] [Related]
15. Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications.
Gagliano A; Germanò E; Pustorino G; Impallomeni C; D'Arrigo C; Calamoneri F; Spina E
J Child Adolesc Psychopharmacol; 2004; 14(1):39-47. PubMed ID: 15142390
[TBL] [Abstract][Full Text] [Related]
16. Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation.
Zuddas A; Di Martino A; Muglia P; Cianchetti C
J Child Adolesc Psychopharmacol; 2000; 10(2):79-90. PubMed ID: 10933118
[TBL] [Abstract][Full Text] [Related]
17. Risperidone in a very young child with PDD.
Bober D; Sabzwari U; Star JE
J Am Acad Child Adolesc Psychiatry; 2005 Aug; 44(8):725-6. PubMed ID: 16034272
[No Abstract] [Full Text] [Related]
18. Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients.
Croonenberghs J; Fegert JM; Findling RL; De Smedt G; Van Dongen S;
J Am Acad Child Adolesc Psychiatry; 2005 Jan; 44(1):64-72. PubMed ID: 15608545
[TBL] [Abstract][Full Text] [Related]
19. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
20. Risperidone monotherapy in manic inpatients: an open label, multicentre trial.
Forsthoff A; Grunze H; Seemüller F; Stampfer R; Dittmann S; Amann B; Schmidt F; Schäfer M; Hermle L; Walden J; Schreiner A
World J Biol Psychiatry; 2007; 8(4):256-61. PubMed ID: 17853251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
